MRK - After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study | Benzinga
Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in combination with maintenance Lynparza (olaparib) for certain patients with metastatic nonsquamous non-small cell lung cancer.
The trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment.
In the KEYLYNK-006 trial, Keytruda in combination with chemotherapy followed by Keytruda plus maintenance Lynparza did not meet the study’s pre-specified statistical criteria for OS or PFS compared to Keytruda in combination with ...